HIGHLIGHTS
- who: Joshua D. Rosenblat and colleagues from the University Health Network, University of Toronto, Toronto, ON M S , Canada have published the research work: A Phase II, Open-Label Clinical Trial of Intranasal Ketamine for Depression in Patients with Cancer Receiving Palliative Care (INKeD-PC Study), in the Journal: Cancers 2023, x of /2023/
- what: This study had a 3.5-year recruitment period (September 2018 to November 2021) to determine the merit and feasibility of a future RCT in the proposed setting and population based on the observed antidepressant efficacy, safety, tolerability, acceptability and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.